UK pricing and marketing
Post# of 148179
(Total Views: 679)
Posted On: 10/27/2020 10:40:23 AM
UK pricing and marketing
From a report by the House Ways and Means Committee last year, it looks like the average drug pricing for the UK is about 3-4 times less than the US. So that would be $8,000-12,000 per patient per year. With 100,000 patients total in the UK, 5% on leronlimab would be around $50M a year although I have no idea what kind of adoption we could expect as part of combo therapy, or if off-label mono gains traction.
We would still need a deal to have a local salesforce market leronlimab to doctors but I don't imagine it would take much to reach the necessary doctors with the relatively small patient population and probable concentration of patients in London.
From a report by the House Ways and Means Committee last year, it looks like the average drug pricing for the UK is about 3-4 times less than the US. So that would be $8,000-12,000 per patient per year. With 100,000 patients total in the UK, 5% on leronlimab would be around $50M a year although I have no idea what kind of adoption we could expect as part of combo therapy, or if off-label mono gains traction.
We would still need a deal to have a local salesforce market leronlimab to doctors but I don't imagine it would take much to reach the necessary doctors with the relatively small patient population and probable concentration of patients in London.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼